Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -44.41% is 52% above its 5-year average of -92.23%, near the high end of its 5-year range (-321.28%–-32.98%).
21.06% above its 12-month average of -56.25%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -10.02%.
RETURN ON ASSETS (ROA)
-44.41%
RETURN ON ASSETS (ROA) AVG TTM
-56.25%
RETURN ON ASSETS (ROA) AVG 3Y
-49.77%
RETURN ON ASSETS (ROA) AVG 5Y
-92.23%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+21.06%
CURRENT VS 3Y AVG
+10.78%
CURRENT VS 5Y AVG
+51.85%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-37.75%
vs the sector median at left
AN2 Therapeutics, Inc.
Market Cap
$182.60M
Return on Assets (ROA)
-44.41%
TTM Avg
-56.25%
3Y Avg
-49.77%
5Y Avg
-92.23%
Market Cap
$180.47M
Return on Assets (ROA)
-17.38%
TTM Avg
-167.34%
3Y Avg
-136.62%
5Y Avg
-286.91%
Market Cap
$179.75M
Return on Assets (ROA)
-38.62%
TTM Avg
-32.73%
3Y Avg
-28.05%
5Y Avg
-37.08%
Market Cap
$179.26M
Return on Assets (ROA)
47.31%
TTM Avg
7.73%
3Y Avg
-1.35%
5Y Avg
-4.55%
Market Cap
$189.11M
Return on Assets (ROA)
-78.16%
TTM Avg
-23.70%
3Y Avg
-68.26%
5Y Avg
-50.80%
Market Cap
$190.07M
Return on Assets (ROA)
-81.22%
TTM Avg
-42.98%
3Y Avg
-45.19%
5Y Avg
-41.10%
Market Cap
$174.27M
Return on Assets (ROA)
-79.26%
TTM Avg
-73.67%
3Y Avg
-58.36%
5Y Avg
-102.57%
Market Cap
$173.76M
Return on Assets (ROA)
-32.29%
TTM Avg
-23.28%
3Y Avg
-25.06%
5Y Avg
-27.38%
Market Cap
$192.49M
Return on Assets (ROA)
-13.31%
TTM Avg
-10.55%
3Y Avg
-23.05%
5Y Avg
-15.01%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | $182.60M | -44.41% | -56.25% | -49.77% | -92.23% |
| Canton Strategic Holdings Inc (CNTN)vs › | $180.47M | -17.38% | -167.34% | -136.62% | -286.91% |
| Compass Therapeutics, Inc. (CMPX)vs › | $179.75M | -38.62% | -32.73% | -28.05% | -37.08% |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $179.26M | 47.31% | 7.73% | -1.35% | -4.55% |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $189.11M | -78.16% | -23.70% | -68.26% | -50.80% |
| Zentalis Pharmaceuticals, Inc. (ZNTL)vs › | $190.07M | -81.22% | -42.98% | -45.19% | -41.10% |
| Yarrow Bioscience Inc (YARW)vs › | $174.27M | -79.26% | -73.67% | -58.36% | -102.57% |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.76M | -32.29% | -23.28% | -25.06% | -27.38% |
| RxSight, Inc. (RXST)vs › | $192.49M | -13.31% | -10.55% | -23.05% | -15.01% |
| Organogenesis Holdings Inc. (ORGO)vs › | $172.42M | -22.20% | 3.18% | 2.72% | 6.35% |
ROA
-44.4%
ROE
-47.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -56.78% |
| 2024-12-31 | -55.73% |
| 2023-12-31 | -46.66% |
| 2022-12-31 | -39.93% |
| 2021-12-31 | -32.98% |
| 2020-12-31 | -321.28% |
| 2019-12-31 | -593.16% |
